COVID-19-associated mucormycosis: case report and systematic review
| dc.authorid | Ahmet Dilek / 0000-0001-7111-2438 | |
| dc.authorscopusid | Ahmet Dilek / 26028752200 | |
| dc.authorwosid | Ahmet Dilek / AAV-7176-2021 | |
| dc.contributor.author | Dilek, Ahmet | |
| dc.contributor.author | Özaras, Reşat | |
| dc.contributor.author | Özkaya, Şevket | |
| dc.contributor.author | Sünbül, Mustafa | |
| dc.contributor.author | Sen, Elif Itir | |
| dc.contributor.author | Leblebicioglu, Hakan | |
| dc.date.accessioned | 2021-09-07T05:20:28Z | |
| dc.date.available | 2021-09-07T05:20:28Z | |
| dc.date.issued | 2021 | en_US |
| dc.department | İstinye Üniversitesi | en_US |
| dc.description.abstract | Background: Increasing number of patients with COVID-19-associated mucormycosis have been reported, especially from India recently. We have described a patient with COVID-19-associated mucormycosis and, searched and analyzed current medical literature to delineate the characteristics of COVID-19-associated mucormycosis. Method: We reported a patient developed mucormycosis during post-COVID period. We searched literature to describe the incidence, clinical features, and outcomes of COVID-19-associated mucormycosis. Demographic features, risk factors, clinical features, diagnostic methods, treatment and outcome were analyzed. Results: We describe a 54-year-old male, hospitalized due to severe COVID-19 pneumonia. He was given long-term, high doses of systemic steroids. He developed maxillo-fascial mucormycosis and died of sepsis. Our literature search found 30 publications describing 100 patients including present case report. The majority (n = 68) were reported from India. 76% were male. The most commonly seen risk factors were corticosteroid use (90.5%), diabetes (79%), and hypertension (34%). Also, excessive use of broad-spectrum antibiotics were noted in cases. Most frequent involvements were rhino-orbital (50%), followed by rhino-sinusal (17%), and rhino-orbito-cerebral (15%). Death was reported as 33 out of 99 patients (33,3%). Conclusions: Steroid use, diabetes, environmental conditions, excessive use of antibiotics, and hypoxia are main risk factors. Despite medical and surgical treatment, mortality rate is high. A multidisciplinary approach is essential to improve the conditions facilitating the emergence of COVID-19-associated mucormycosis. | en_US |
| dc.identifier.citation | Dilek, A., Ozaras, R., Ozkaya, S., Sunbul, M., Sen, E. I., & Leblebicioglu, H. (2021). COVID-19-associated mucormycosis: Case report and systematic review. Travel Medicine and Infectious Disease, 102148. | en_US |
| dc.identifier.doi | 10.1016/j.tmaid.2021.102148 | en_US |
| dc.identifier.issn | 1477-8939 | en_US |
| dc.identifier.pmid | 34454090 | en_US |
| dc.identifier.scopus | 2-s2.0-85113424438 | en_US |
| dc.identifier.scopusquality | Q1 | en_US |
| dc.identifier.uri | https://doi.org/10.1016/j.tmaid.2021.102148 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12713/2024 | |
| dc.identifier.volume | 44 | en_US |
| dc.identifier.wos | WOS:000703570700003 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.institutionauthor | Dilek, Ahmet | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier Inc. | en_US |
| dc.relation.ispartof | Travel Medicine and Infectious Disease | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Coronavirus | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Fungal Infections | en_US |
| dc.subject | Mucor | en_US |
| dc.subject | Mucormycosis | en_US |
| dc.title | COVID-19-associated mucormycosis: case report and systematic review | en_US |
| dc.type | Review Article | en_US |
